# Fluxome Sciences AS

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/fluxome-sciences

- Industry: Biotechnology
- Headquarters: Denmark
- Website: www.fluxome.com
- Total disclosed funding: $20M
- Latest round: Series B (Jul 22, 2008)
- Investors on record: 4

## About

Fluxome Sciences AS is a biotechnology company specializing in innovative solutions that enhance operational efficiency and streamline processes for various industries.Fluxome Sciences AS, founded in 2002 in Denmark, focuses on the development of advanced technologies for operational efficiency. The company has undergone funding rounds to support its growth, with its latest funding round, the TRADE SALE, occurring on November 21, 2012, where it raised CHF 0.25 million from Evolva Holding SA. The company has completed a total of four deals and does not have any subsidiaries or parent companies. The founder's information is not publicly detailed.Fluxome.com specializes in delivering innovative solutions tailored to meet the diverse needs of its clientele. The company's core product offerings revolve around advanced technologies designed to enhance operational efficiency and streamline processes across various industries. These products are developed with a focus on addressing specific challenges faced by businesses, thereby enabling them to optimize performance and drive growth. Their customer base includes a range of sectors, from technology to manufacturing, with end users benefiting from enhanced productivity and reduced operational costs. Fluxome.com primarily serves markets in North America and Europe, ensuring that their products are accessible to a broad audience while remaining aligned with industry standards and regulations.In the most recent year of 2011, Fluxome Sciences AS reported a revenue of CHF 0.00 and an EBITDA of CHF -5,449,439.As part of its future growth strategy, Fluxome Sciences AS plans to leverage its recent TRADE SALE funding to expand its product offerings and enter new geographic markets. The acquisition of scientific and technical assets related to resveratrol by Evolva Holding SA will facilitate new product launches aimed at the biotechnology sector. The company is focusing on enhancing its presence in both North America and Europe while exploring potential markets in Asia by 2014. The recent funding of CHF 0.25 million will be utilized to support these initiatives.

## Funding rounds

- Series B, Jul 22, 2008, $20M — Capricorn Partners, Seventure Partners, Incuba Venture, Vecata

## Investors

- Capricorn Partners (https://capitalatlas.ai/funds/capricorn-partners) — Series B
- Seventure Partners (https://capitalatlas.ai/funds/seventure-partners) — Series B
- Incuba Venture — Series B
- Vecata — Series B